title: Tubal patency after clinical treatment of unruptured ectopic pregnancy.
abstract: OBJECTIVE
  To evaluate tubal patency using hysterosalpingography after clinical treatment of tubal pregnancy.
  
  
  METHODS
  Of 80 patients who underwent hysterosalpingography after clinical treatment of tubal pregnancy from April 1994 to February 2002, 30 were treated with a single 50 mg/m(2) dose of methotrexate intramuscularly (n=30) and 50 were followed up expectantly.
  
  
  RESULTS
  Patency of the ipsilateral tube was 84% after methotrexate treatment and 78% after expectant management. In addition, contralateral tubal patency was 97% after methotrexate treatment and 92% after expectant management. There were no statistically significant differences between the groups.
  
  
  CONCLUSIONS
  Findings from this study suggest similar tubal patency rates after methotrexate treatment and expectant management.
authors.affiliation: Department of Obstetrics of the Escola Paulista de Medicina, Federal University of São Paulo, Rua Maria Carolina, 68, Jardim Paulistano CEP-01445-000, São Paulo, Brazil. elitojjr@hotmail.com
authors.forename: J
authors.initials: J
authors.lastname: Elito
authors.forename: K K
authors.initials: KK
authors.lastname: Han
authors.forename: L
authors.initials: L
authors.lastname: Camano
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000627:therapeutic use; D005187:Fallopian Tubes / Q000502:physiology*; D005260:Female; D006801:Humans; D007047:Hysterosalpingography; D008727:Methotrexate / Q000627:therapeutic use; D011247:Pregnancy; D011274:Pregnancy, Tubal / Q000188:drug therapy / Q000601:surgery*; D011446:Prospective Studies; D020127:Recovery of Function
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D008727:Methotrexate